Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension is characterized by residual tissue clots that block the pulmonary vasculature 1, leading to increased pulmonary vascular resistance, progressive pulmonary hypertension, and right ventricular failure. Patients with chronic thromboembolic pulmonary hypertension have a poor prognosis unless they receive early treatment.

  • Pulmonary endarterectomy
  • chronic thromboembolic

Related Conference of Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

August 27-28, 2026

40th European Cardiology Conference

Berlin, Germany
October 20-21, 2026

15th World Heart Congress

London, UK
November 09-10, 2026

7th Annual Summit on Cardiology and Heart Diseases

Paris, France
November 16-17, 2026

8th World Heart Congress

Tokyo, Japan
November 23-24, 2026

40th World Congress on Heart Diseases

Toronto, Canada
November 25-26, 2026

33rd World Heartcare Summit

Paris, France
January 26-27, 2027

12th International Heart Conference

Dubai, UAE
March 18-19, 2027

16th World Heart Congress

Paris, France
May 13-14, 2027

10th Annual Heart Rhythm Conference

Rome, Italy
June 17-18, 2027

10th World Heart and Brain Conference

London, UK
June 21-22, 2027

8th European Summit on Cardiology Research

Zurich, Switzerland

Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in